The European Platform for Neurodegenerative Diseases has created a Cohort Catalogue to help to accelerate the hunt for biological markers of neurodegenerative diseases like Alzheimer's and Parkinson's diseases.
A drop off in the number of commercially led trials has had an opportunity cost for UK taxpayers of an estimated £360 million over the past five years, says government commissioned review
Some research lobbies are concerned the decision to publish less information on Commission staff will make their work more complicated, saying ‘it is very much to the detriment of the research & innovation community.’ Others don’t care so much
Delays in getting the CE mark for medical devices are stretching the resources of European start-ups and forcing some to turn their attention to the US
Proposal is more than this year, but sky-high inflation devalues the increase. The European Parliament is pinning its hopes on extracting more in the mid-term EU budget review, but rocketing interest payments leave little room for manoeuvre
Half of postdocs say they don’t have access to social security, a situation made even worse because many don’t have permanent contracts either. Now campaigners are putting pressure on the EU to lean on member states to improve working conditions for Europe’s young scientists
The government withheld funding for a research institute after objecting to the views of one of its scholars. Researchers say this is an attempt ‘to intimidate scholars whose research might result in refutations of opinions held by some politicians’
Toomas Asser, recently appointed for a second term at the helm of the University of Tartu, has big plans for changing how knowledge is translated from lab to market
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.